Dear member,

welcome to this years first edition of the membership online letter.

Your ESOP Membershipservice



Since 2010 we have had a new structure of ESOP - Commitees. Unfortunately to the most of them belong only one person. Commitees must be a strong and powerfull network of people form different countries. More members allow us to work more hardly and effective. As a consequence the promotion of ESOP activity will we stronger and faster. Therefore we would like to invite to our committee.
Good wills are welcome to join the committee! Below you can find a short describtions of difference committees.

Publication committee
Practice Committee
Research Committee
Scientific Committee

Organization committee

Education Committee






Dear ESOP Members,
According to our final arrangements during our meeting in Hamburg, I am happy to invite you to edit of our home page and Newsletter. ‘News from other country’ is a new section of our Newsletter. Here you can find informations from ours European colleagues and friends. We would like to put here the new practical informations, reports and events description. It would be great if you could write a few words about news, development and practice of oncology pharmacy in your country. The level of oncology pharmacy in Europe is different, therefore your knowledge and experience may help others to start.

Lukasz Lapinski



In Bosnia & Herzegovina has not developed oncology pharmacy yet, but pharmacists have been working hardly on that. On 16th of April it will be held a meeting of Section for Hospital/Clinical Pharmacy of Bosnia & Herzegovina when working group for oncology pharmacy will be constituted. It will be a few lecturers coming from surrounding countries and one from the UK to share their experiences on implementing centralized preparation and oncology pharmacy in their countries.

Tijana Marinkovic



The French Society of Oncology Pharmacy (SFPO) is continuing its work on the publication of practical guidelines. As an example, in the last issue of EJOP, the SFPO and ESOP recommendations on stability of anticancer drugs have been published (1). These recommendations were the English translated and updated version of the recommendations issued from a working group of our society, initially published and disseminated in French in 2008. These updated recommendations were endorsed by ESOP in 2010.
Similarly, very recently, SFPO has furnished a consensus conference concerning the remnant question of the simultaneous preparation of monoclonal antibodies and cytotoxic drugs in the same working area. Indeed, in France, some pharmacy inspectors from regulation authorities asked several hospital pharmacies to use separate areas to handle both categories of drugs. The surrounding idea is the possibility of cross-contamination; i.e. the contamination of a monoclonal antibodies by traces of a cytotoxic drug prepared just before. However, there is no convincing publication that sterile transfer operations in closed systems can induce cross –contaminations, as compared to operations with open systems where they might exist. In the opposite, a very recent study from colleagues from the Geneva University Hospital (2) demonstrated no cross-contamination using a very-well designed experimental design mimicking current practices in handling anticancer drugs. Therefore, considering the additional costs and increased difficulties induced by a mandatory separation of the working areas, SFPO decided to set-up a working group to analyze the problem and all publications related to cross-contamination in sterile areas. It has been concluded that there is no risk to prepare monoclonal antibodies and cytotoxic drugs in the same area if normal good manufacturing procedures are followed. The results of this working group has been published as a “consensus conference” and distributed to members of the SFPO. This recommendation should be discussed at European level to exam the possibility to endorsement by ESOP.

Prof. Alain Astier

  1. Astier A., Pinguet F., Vigneron J.: The practical stability or anticancer drugs: SFPO and ESOP recommendations. Eur. J. Oncol. Pharm., 2010, 4, 4-10.
  2. Ramseyer J., Sadeghipour F., Bonnabry P.: Mesure de la contamination chimique croisée lors de la préparation d’injectables et de formes sèches de médicaments toxiques. Maitrise Universitaire en Pharmacie, Genève, 2010 (http://pharmacie.hug-ge.ch/ens/travmaitrise/2010_contamination_ramseyer.pdf)



Estonian Hospital Pharmacy Association had  their annual 16th Spring Conference in Viljandi (4 and 5 March) where this year’s main topic was skin. We had lectures from different type of skin diseases and got an overview about skin cancer and selected therapies.

Kristjan Kongi




2010 was the most successful year from the beginning. We have taken an official invitation from  Turkish Grand National Assembly, Cancer Investigation & Research Commission for informing about new developments on Cytotoxic drugs' preparation techniques. It was a big chance to present ourselves and our association to deputies. January of 2011, the commission finished the preparation of the report, and Turkish Oncology Pharmacists Association  took a place in the report. We organized the 4th Cytotoxic Drug Preparation Techniques & Safe Room Management Training Program. Currently, this program is organizing every six months. We are also working on continuing education. For continuing education, it is the best way is to use the internet because oncology pharmacists are still working all over the country.
We opened the Oncology Pharmacy Technicians Platform on a web page for generating a discussion medium. We organized Case Report Discussions and each of us  working and discussing the same questions over internet forum pages every month. This idea was such, interesting and intriguing, so we translated them and sent to ESOP delegates. ESOP Board published them in ESOP website. We hope Case Report Discussions will be a value all over the Europe and whole Earth in near future. All Oncology Pharmacy Association members are volunteers. They are going to Pharmacy Faculties to introduce their Oncology Pharmacy carrier. At the same time, every unit is a training area for pharmacy students.
We attended to Master Class Programs in Slovenia and ECCO Meeting in Brussels this year. Our base project was starting to write Chemotherapy Management Standards as named SAFE&SAFER. It is a brand name, and it is near translation of QUAPOS with domestic identities. We have started to publish the OEDD Journal of Oncology Pharmacists. We published 200 issues and postage them to colleagues, associations, deputies, and, etc. We believe that every Oncology Pharmacist has an academic viewpoint. However, as a first stage, we sent a poster to Medical Oncology Physician’s Congress.
 Future?

  1. To publish more case reports also Turkish and English for OED and ESOP web pages.
  2. To publish new issues of the Journal of Oncology Pharmacists.
  3. Collaborate and prepare a multicenter researches  with our newborn association named Infection & Nutrition Support Pharmacy Association.
  4. To organize a new certificated training program for technicians.

Over the last three-year, oncology pharmacists have gained and consolidated a strong position within the oncology team in Turkish hospitals.  At advanced stage, we are planning to support a consolidation of pharmaceutical knowledge regarding topics in supportive care. We want to develop to manage possible adverse events, explicit patient recommendations and specific information about individual prescribed drugs by oncology pharmacists.

Ahmet Bosnak





We invite you to learn and analyze a new case report – Non-small cell lung adenocarcinoma with lung metastasis and lymphangitis carcinomatosis.
(http://www.esop.li/downloads/casereport012011.pdf)
The next will be published soon.
If you have other case reports do not hesitate to contact with Lukasz Lapinski (ll@esop.li)